ONL logo.jpg
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022 07:00 ET | ONL Therapeutics
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – –...
ONL logo.jpg
ONL Therapeutics Names Connie Chang as Chief Operating Officer
January 19, 2021 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL logo.jpg
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
BSN-Logo-color.jpg
Big Switch to Demo SONiC with Open Network Linux at OCP Summit
March 12, 2019 06:15 ET | Big Switch Networks
SANTA CLARA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Big Switch Networks®, The Cloud-First Networking Company, will demonstrate an open-source network operating system (NOS) at the OCP Summit...
BSN-Logo-color.jpg
Facebook, Google and Big Switch Networks to Demonstrate Open Source Collaboration with Next-Gen Network Operating Systems During OCP Summit Keynote
March 19, 2018 03:15 ET | Big Switch Networks
SANTA CLARA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Big Switch Networks®, the Next-generation Data Center Networking Company, will present an OCP Summit keynote with Facebook and Google, to...